Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Icotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 17/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | BUB1 | O43683 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | CARS1 | P49589 | 1/20 | 1.00 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 1.00 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 1.00 |
| ▸ | SLK | Q9H2G2 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 4/20 | 0.64 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.64 |
| ▸ | SRC | P12931 | 4/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.64 |
| ▸ | FBP1 | P09467 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Icotinib SCHEMBL29544144 | 1.00 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| Icotinib SCHEMBL5843603 | 1.00 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| Icotinib SCHEMBL29376848 | 0.99 | EGFR (0.98) | EGFRGAKRIPK2BUB1STK10 | |
| Icotinib SCHEMBL31236202 | 0.99 | EGFR (0.98) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL20865234 | 0.97 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL19039352 | 0.93 | EGFR (0.87) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL1507604 | 0.90 | EGFR (0.87) | EGFRGAKRIPK2BUB1STK10 | |
| Hydrochloric Acid SCHEMBL1507697 | 0.89 | EGFR (0.85) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL15339251 | 0.88 | EGFR (0.79) | EGFRGAKRIPK2BUB1STK10 | |
| SCHEMBL31004062 | 0.85 | EGFR (1.00) | EGFRGAKRIPK2BUB1STK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3171 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746970-A1 | EGFR ANTAGONISTS FOR THE TREATMENT OF DISEASES INVOLVING UNWANTED MIGRATION, PROLIFERATION, AND/OR METAPLASIA OF RETINAL PIGMENT EPITHELIUM (RPE) CELLS | Jonas, Jost B. (DE) | 2026-05-27 | — | — | EP | claimed |
| EP-4747285-A1 | MONOCLONAL ANTIBODIES AGAINST PCDH7 FOR LUNG CANCER THERAPY | The Board of Regents of the University of Texas System (US) | 2026-05-27 | — | — | EP | claimed |
| CN-122075716-A | Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| US-20260137678-A1 | METHODS FOR TREATING OR PREVENTING NEUROENDOCRINE TUMOR FORMATION USING XPO1 INHIBITORS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026103823-A1 | COMBINATION OF RAS INHIBITOR AND EGFR INHIBITOR AND USE THEREOF | 广州嘉越医药科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| CN-122070138-A | Compositions and methods for expressing EGFR | 瑞普利科特生物科学公司 | 2026-05-19 | — | — | CN | claimed |
| US-20260130856-A1 | LIPOSOME COMPOSITIONS FOR DELIVERY OF COMPOUNDS AND METHODS THEREOF | NANOTECH PHARMA INC (US) | 2026-05-14 | — | — | US | claimed |
| EP-4741395-A1 | NOVEL COMPOUND SENSITIVE TO NITROGEN MONOXIDE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Omniamed Co. Ltd (KR) | 2026-05-13 | — | — | EP | claimed |
| CN-122029214-A | Phospholipid drug conjugate and preparation method and application thereof | 上海弼领生物技术有限公司 | 2026-05-12 | — | — | CN | claimed |
| CN-111763214-B | Preparation method of icotinib | 苏州富士莱医药股份有限公司 | 2022-03-15 | — | — | CN | claimed |
| EP-3964217-A1 | USE OF COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT, DIMER OR TRIMER THEREOF IN PREPARATION OF DRUG FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-03-09 | — | — | EP | claimed |
| WO-2022045976-A1 | METHOD OF MODULATING SENSITIVITY TO TYROSINE KINASE INHIBITOR | SINGAPORE HEALTH SERVICES PTE LTD (SG) | 2022-03-03 | — | — | WO | claimed |
| EP-3957631-A1 | QUINOLINE COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING EWING'S SARCOMA | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| EP-3957310-A1 | COMPOSITION AND USE THEREOF IN PREPARATION OF MEDICATION FOR TREATING CANCER | Newish Technology (Beijing) Co., Ltd. (CN) | 2022-02-23 | — | — | EP | claimed |
| CN-111362957-B | Preparation method of icotinib key intermediate | 上海百利佳生医药科技有限公司 | 2022-02-18 | — | — | CN | claimed |
| WO-2022032943-A1 | PREPARATION METHOD FOR ICOTINIB | 苏州富士莱医药股份有限公司 | 2022-02-17 | — | — | WO | claimed |
| CN-111909163-B | Quinolamine compound with IDO1 inhibition function and preparation method thereof | 南开大学 | 2022-02-01 | — | — | CN | claimed |
| WO-2022016844-A1 | INTERFERON-BASED CANCER TREATMENT METHOD AND PHARMACEUTICAL COMPOSITION | 厦门特宝生物工程股份有限公司 | 2022-01-27 | — | — | WO | claimed |
| EP-3942045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KINASE INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2022-01-26 | — | — | EP | claimed |